Traditional Chinese medicine composition for treating leucopenia as well as preparation method and application of traditional Chinese medicine composition

Abstract

The invention provides a traditional Chinese medicine composition for treating leucopenia as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for treating leucopenia is prepared from the following raw materials in parts by weight: 10-20 parts of ginseng, 10-30 parts of lucid ganoderma, 15-30 parts of astragalus membranaceus, 10-20 parts of rhizoma polygonati and 10-30 parts of venison. According to the traditional Chinese medicine composition, all the medicinal materials can achieve a synergistic effect, the bone marrow hematopoiesis function is promoted, generation and release of leucocytes are accelerated, leucopenia caused by bone marrow suppression can be remarkably improved, the immunity of the organism is improved, the life quality of a patient is improved, and the traditional Chinese medicine composition is high in safety, small in side effect and suitable for being taken for a long time.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular to a traditional Chinese medicine composition for treating leukocytopenia, and a preparation method and application thereof. Background Art

[0002] Cancer (malignant tumor) refers to a disease characterized by the development of abnormal cells. Such abnormal cells divide uncontrollably and have the ability to infiltrate and destroy normal human tissues. Cancer is often manifested by the appearance of lumps, pain, ulcers, bleeding, obstruction and other abnormalities in the body for unknown reasons. The cause of cancer is still unclear. It is generally believed that it may be related to various factors such as genetic genes, environmental pollution, radiation, and bad habits. Cancer is the second leading cause of death in the world. At present, chemotherapy is an indispensable means of clinical treatment for patients with malignant tumors. However, chemotherapy drugs are toxic and cannot distinguish between good and bad. While killing wildly growing and proliferating cancer cells, they will also kill other human cells. Therefore, patients receiving chemotherapy will experience various adverse reactions. The most common of these are bone marrow suppression and immune function damage. After bone marrow suppression, patients mainly show leukopenia, low immunity, anemia, susceptibility to infection, etc., which have an adverse effect on the recovery of the disease. Existing patents CN 110269924 A, published on September 24, 2019, and CN 104258203 A, published on January 7, 2015, both disclose a Chinese medicine composition for treating leukopenia, but the formula contains a large amount of Chinese medicine, and the patient needs to consume a lot of body functions to metabolize these drugs. Although it can treat leukopenia in chemotherapy patients, it also inevitably brings a greater burden to the patient's body.

[0003] Therefore, providing a simplified Chinese medicine composition that can significantly alleviate leukopenia in patients after chemotherapy and increase the number of white blood cells can significantly reduce the patient's physical burden and effectively improve the quality of life of chemotherapy patients. Summary of the invention

[0004] The purpose of the present invention is to provide a Chinese medicine composition for treating leukocytopenia, which can significantly increase the number of white blood cells, enhance immunity and improve the quality of life of patients.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The invention provides a traditional Chinese medicine composition for treating leukocytopenia. The composition is composed of the following raw materials in parts by weight: 10-20 parts of ginseng, 10-30 parts of ganoderma lucidum, 15-30 parts of astragalus, 10-20 parts of polygonatum and 10-30 parts of venison.

[0007] The present invention also provides a method for preparing the above-mentioned Chinese medicine composition, comprising the following steps:

[0008] (1) Mix ginseng, ganoderma lucidum, astragalus and polygonatum, and add water to soak;

[0009] (2) boiling the Chinese medicine soaked in step (1) with soaking water, and filtering to obtain a decoction;

[0010] (3) adding water to the residue obtained by filtering in step (2) and continuing to boil, filtering to obtain a decoction, and repeating 2 to 4 times;

[0011] (4) combining the decoctions of steps (2) and (3) to obtain a Chinese medicine solution;

[0012] (5) adding water to venison to boil, filtering and taking out the decoction, and mixing it with the Chinese medicine liquid of step (4) to obtain a Chinese medicine composition.

[0013] Preferably, the amount of water added in step (1) is 3 to 5 times the total weight of the medicinal materials; and the soaking time is 2 to 3 hours.

[0014] Preferably, the decocting time in step (2) is 1 to 2 hours.

[0015] Preferably, the amount of water added in step (3) is 3 to 5 times the amount of the medicinal residue, and the decoction is continued for 1 to 2 hours.

[0016] Preferably, the amount of water added in step (5) is 3 to 5 times the weight of the venison, and the frying time is 2 to 3 hours.

[0017] The present invention also provides an application of the above-mentioned Chinese medicine composition or the Chinese medicine composition prepared by the above-mentioned preparation method in preparing a medicine for treating leukopenia.

[0018] Preferably, the leukopenia includes leukopenia caused by autoimmune disease, radiotherapy and chemotherapy.

[0019] Preferably, the drug further comprises pharmaceutically acceptable excipients, and the dosage forms of the drug include ointments, pills, capsules and oral liquids.

[0020] The present invention prepares a Chinese medicine composition by using ginseng, ganoderma lucidum, astragalus, polygonatum and venison, wherein ginseng, astragalus and polygonatum have the effects of invigorating qi and nourishing blood, can improve the symptoms of qi deficiency and blood deficiency, and promote the generation of leukocytes; ganoderma lucidum and ginseng have the effects of enhancing immunity, can activate immune cells, improve the body's resistance, and help the recovery of the number of leukocytes; venison can promote blood circulation, enhance immunity, and assist the generation of leukocytes. The medicinal materials in the prescription can act synergistically, promote bone marrow hematopoietic function, accelerate the generation and release of leukocytes, can significantly improve leukopenia caused by bone marrow suppression, improve the body's immunity, improve the quality of life of patients, and have high safety, small side effects, and are suitable for long-term use. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 The number of white blood cells in each group of mice after modeling in Example 4;

[0022] Figure 2 The number of neutrophils in each group of mice after modeling in Example 4;

[0023] Figure 3 The number of lymphocytes in each group of mice after modeling in Example 4;

[0024] Figure 4 The number of white blood cells in each group of mice after 7 days of administration in Example 5;

[0025] Figure 5 The number of neutrophils in each group of mice after 7 days of administration in Example 5;

[0026] Figure 6 The lymphocyte numbers of mice in each group 7 days after administration in Example 5. DETAILED DESCRIPTION

[0027] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0028] Example 1

[0029] Weigh 15g of ginseng, 20g of ganoderma lucidum, 20g of astragalus, and 15g of polygonatum, add them to 280g of water, soak for 2h, decoct with soaking water for 1h, and filter to obtain a decoction. Take the medicinal residue and add 4 times the weight of water, continue to decoct for 1h, filter to obtain a decoction, repeat the decoction 3 times, filter to obtain a decoction, combine the 5 decoctions to obtain a Chinese medicine liquid. Weigh 20g of venison, add 80g of water and decoct for 3h, filter the soup, and mix it with the Chinese medicine liquid to obtain a Chinese medicine composition.

[0030] Example 2

[0031] Weigh 10g of ginseng, 10g of ganoderma lucidum, 15g of astragalus, and 10g of polygonatum, add them to 135g of water, soak for 2h, decoct with soaking water for 2h, and filter to obtain a decoction. Take the medicinal residue and add 3 times the weight of water, continue to decoct for 2h, filter to obtain a decoction, repeat the decoction 2 times, filter to obtain a decoction, and combine the 4 decoctions to obtain a Chinese medicine liquid. Weigh 10g of venison, add 30g of water and decoct for 3h, filter the soup, and mix it with the Chinese medicine liquid to obtain a Chinese medicine composition.

[0032] Example 3

[0033] Weigh 20g of ginseng, 30g of ganoderma lucidum, 30g of astragalus, and 20g of polygonatum, add them to 500g of water, soak for 3h, decoct with soaking water for 2h, and filter to obtain a decoction. Take the residue and add 5 times the weight of water, continue to decoct for 1.5h, filter to obtain a decoction, repeat the decoction 2 times, filter to obtain a decoction, and combine the 4 decoctions to obtain a Chinese medicine liquid. Weigh 30g of venison, add 150g of water and decoct for 3h, filter the soup, and mix it with the Chinese medicine liquid to obtain a Chinese medicine composition.

[0034] Example 4

[0035] The experiment used 56 SPF male 8-week-old Balb / C mice (body weight 20±2g), which were fully fed under experimental conditions and room temperature 20-26℃. After one week of adaptive feeding, the mice were randomly divided into 7 groups, including blank group, model group, low-, medium- and high-dose drug groups, positive control group A (levamisole hydrochloride) and positive control group B (Diyu Shengbai tablets), with 8 mice in each group. Except for the blank group, the mice in the other groups were intraperitoneally injected with 100μL cyclophosphamide solution (80mg / kg) to establish an immunocompromised mouse model. The blank group was intraperitoneally injected with an equal volume of normal saline for 3 consecutive days. 20μL of blood was collected from the tip of the tail for blood routine testing. The results are shown in Tables 1 and Figures 1 to 3 As shown ( Figures 1 to 3 1 to 7 in the table represent blank group, model group, positive control group A, positive control group B, low-dose drug group, medium-dose drug group, and high-dose drug group, respectively).

[0036] Table 1 The number of white blood cells, neutrophils and lymphocytes in each group of mice after modeling

[0037]

[0038] Note: Compared with the blank group***P<0.0001

[0039] According to Table 1 and Figures 1 to 3 The results showed that compared with the blank group, the numbers of white blood cells, neutrophils and lymphocytes in the other 6 groups given cyclophosphamide solution were significantly decreased, indicating that the cyclophosphamide-induced bone marrow suppression model was successfully established.

[0040] Example 5

[0041] Subsequent experiments were conducted using mice successfully modeled in Example 4 to verify whether the Chinese medicine composition prepared by the present invention has the effect of increasing the number of white blood cells in mice with bone marrow suppression. The blank group and the model group mice were given distilled water, the positive control group A was given 40 mg / kg of levamisole hydrochloride, and the positive control group B was given 100 mg / kg of Diyu Shengbai Tablets. The low-, medium-, and high-dose groups of the drug were given 1.6, 3.3, and 6.6 g / kg of the Chinese medicine composition prepared in Example 1, respectively, for 7 consecutive days, with a dosage of 10 mL / kg per day. After 7 days, the tails of the 6 groups of mice were cut and 20 μL of blood was collected to measure blood routine. The results are shown in Tables 2 and Figures 4 to 6 As shown ( Figures 4 to 6 1 to 7 represent the blank group, model group, positive control group A, positive control group B, low-dose drug group, medium-dose drug group, and high-dose drug group, respectively.

[0042] Table 2 The number of white blood cells, neutrophils and lymphocytes in each group of mice after 7 days of administration

[0043]

[0044] Note: Compared with the model group***P<0.0001

[0045] According to Table 2 and Figures 4 to 6 It can be seen that the low, medium and high dose groups of the drug prepared in this application have significantly increased the number of white blood cells, the number of neutrophils and the number of lymphocytes compared with the model group, especially the number of neutrophils has a more significant increase. Among them, the medium dose group of the drug has a better improvement effect than the low and high dose groups. It can be seen that the Chinese medicine combination prepared in this application can significantly improve leukopenia caused by bone marrow suppression, can significantly increase the number of white blood cells within 7 days, and enhance immunity.

[0046] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A Chinese medicine composition for treating leukocytopenia, characterized in that: The invention is composed of the following raw materials in parts by weight: 10-20 parts of ginseng, 10-30 parts of ganoderma lucidum, 15-30 parts of astragalus, 10-20 parts of polygonatum and 10-30 parts of venison.

2. A method for preparing the Chinese medicine composition according to claim 1, characterized in that: The following steps are involved: (1) Mix ginseng, ganoderma lucidum, astragalus and polygonatum, and add water to soak; (2) boiling the Chinese medicine soaked in step (1) with soaking water, and filtering to obtain a decoction; (3) adding water to the residue obtained by filtering in step (2) and continuing to boil, filtering to obtain a decoction, and repeating 2 to 4 times; (4) combining the decoctions of steps (2) and (3) to obtain a Chinese medicine solution; (5) adding water to venison to boil, filtering and taking out the decoction, and mixing it with the Chinese medicine liquid of step (4) to obtain a Chinese medicine composition.

3. The preparation method as claimed in claim 2, characterized in that The amount of water added in step (1) is 3 to 5 times the total weight of the medicinal materials; and the soaking time is 2 to 3 hours.

4. The preparation method as claimed in claim 2, characterized in that The decoction time in step (2) is 1 to 2 hours.

5. The preparation method as claimed in claim 2, characterized in that: In the step (3), the amount of water added is 3 to 5 times the amount of the medicinal residue, and the decoction is continued for 1 to 2 hours.

6. The preparation method as claimed in claim 2, characterized in that In step (5), the amount of water added is 3 to 5 times the weight of the venison, and the decocting time is 2 to 3 hours.

7. Use of the Chinese medicine composition according to claim 1 or the Chinese medicine composition prepared by the preparation method according to any one of claims 2 to 6 in preparing a drug for treating leukopenia.

8. The use according to claim 7, characterized in that The leukopenia includes leukopenia caused by autoimmune diseases, radiotherapy and chemotherapy.

9. The use according to claim 7, characterized in that The medicine also includes pharmaceutically acceptable auxiliary materials, and the dosage forms of the medicine include ointment, pills, capsules and oral liquid.

Images